Literature DB >> 19896084

A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions.

Juliet N Barker1, Michelle Abboud, Robert D Rice, Rebecca Hawke, Allison Schaible, Glenn Heller, Vincent La Russa, Andromachi Scaradavou.   

Abstract

Preparation of cord blood (CB) units for infusion by albumin-dextran dilution without centrifugation may be advantageous for adult patients to minimize cell loss and, unlike a bedside thaw, is still conducted in the controlled laboratory environment. Therefore, we studied CB transplantation (CBT) using this technique in 54 consecutive CBT recipients >20 kg. Patients (median age=42 years [range: 7-66 years]; median weight=71 kg [range: 24-109]) were transplanted for high-risk hematologic malignancies with myeloablative (n=35) or nonmyeloablative (n=19) conditioning and 4-6/6 human leukocyte antigen (HLA)-matched double-unit grafts. One hundred seven units were thawed with dilution, whereas 1 red blood cell (RBC)-replete unit was washed. A 5:1 dextran 40%/25% albumin solution was used. RBC-depleted units (n=104) were diluted >or=5.5-fold (median final volume 200 mL [range: 200-500]), whereas RBC-replete units (n=3) were diluted >or=4-fold (median final volume 400 mL [range: 400-535]). Total nucleated cell (TNC) recovery was 86%; the median infused TNC dose was 2.17x10(7)/kg/unit. Although 35 patients (65%) had a total of 45 infusion reactions (6 nausea, 31 hypertension, 3 pain, 1 rigors/fever, 2 transient hypoxia, 2 renal impairment) requiring additional therapy, there were no infusion-related serious adverse events, and reactions were not related to dimethyl sulfoxide (DMSO) dose/kg. Cumulative incidence of sustained donor engraftment was 94% (95% cumulative incidence [CI]: 87-100) with neutrophil recovery occurring at a median of 25 days (range: 13-43) in myeloablative and 10 days (range: 7-36) in nonmyeloablative recipients. CB thaw with albumin-dextran dilution reduces unit manipulation, and minimizes cell loss, speeds time to infusion, is associated with a tolerable infusion reaction profile, and a high rate of sustained engraftment in CBT recipients >or=20 kg.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896084      PMCID: PMC3105472          DOI: 10.1016/j.bbmt.2009.08.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment.

Authors:  T Hahn; U Bunworasate; M C George; A S Bir; W Chinratanalab; A R Alam; B Bambach; M R Baer; J L Slack; M Wetzler; J L Becker; P L McCarthy
Journal:  Bone Marrow Transplant       Date:  2003-07       Impact factor: 5.483

Review 2.  Patient care during infusion of hematopoietic progenitor cells.

Authors:  Annette Sauer-Heilborn; Diane Kadidlo; Jeffrey McCullough
Journal:  Transfusion       Date:  2004-06       Impact factor: 3.157

3.  Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples.

Authors:  Vincent Laroche; David H McKenna; Gary Moroff; Therese Schierman; Diane Kadidlo; Jeffrey McCullough
Journal:  Transfusion       Date:  2005-12       Impact factor: 3.157

4.  IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.

Authors:  P A Rowlings; D Przepiorka; J P Klein; R P Gale; J R Passweg; P J Henslee-Downey; J Y Cahn; S Calderwood; A Gratwohl; G Socié; M M Abecasis; K A Sobocinski; M J Zhang; M M Horowitz
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

5.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.

Authors:  P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

7.  Differential sensitivity to cryopreservation of clonogenic progenitor cells and stromal precursors from leukemic and normal bone marrow.

Authors:  H A Zaheer; F M Gibson; M Bagnara; E C Gordon-Smith; T R Rutherford
Journal:  Stem Cells       Date:  1994-03       Impact factor: 6.277

8.  Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced.

Authors:  Robert Chow; Auayporn Nademanee; Joseph Rosenthal; Chatchada Karanes; Tang-Her Jaing; Michael L Graham; Elsa Tsukahara; Brian Wang; David Gjertson; Patrick Tan; Stephen Forman; Lawrence D Petz
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-21       Impact factor: 5.742

9.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

10.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

  10 in total
  26 in total

1.  A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.

Authors:  U Sobol; A Go; S Kliethermes; S Bufalino; T Rodriguez; S Smith; M Parthasarathy; P Stiff
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  A severe umbilical cord stem cell infusion reaction due to dextran in an atopic pediatric patient.

Authors:  L Cooling; A Sankar; R Mody; G Yanik; C Bonifant; S W Choi
Journal:  Bone Marrow Transplant       Date:  2017-03-06       Impact factor: 5.483

3.  Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Authors:  D M Ponce; A Gonzales; M Lubin; H Castro-Malaspina; S Giralt; J D Goldberg; A M Hanash; A Jakubowski; R Jenq; E B Papadopoulos; M A Perales; M R M van den Brink; J W Young; F Boulad; R J O'Reilly; S Prockop; T N Small; A Scaradavou; N A Kernan; C E Stevens; J N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

4.  Adverse reactions during stem cell infusion in children treated with autologous and allogeneic stem cell transplantation.

Authors:  T H Truong; R Moorjani; D Dewey; G M T Guilcher; N L Prokopishyn; V A Lewis
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

5.  Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice.

Authors:  Duncan Purtill; Katherine Smith; Sean Devlin; Richard Meagher; Joann Tonon; Marissa Lubin; Doris M Ponce; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Cladd E Stevens; Juliet N Barker
Journal:  Blood       Date:  2014-09-02       Impact factor: 22.113

6.  The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.

Authors:  Doris M Ponce; Marissa Lubin; Anne Marie Gonzales; Courtney Byam; Deborah Wells; Rosanna Ferrante; Glenn Heller; Sergio Giralt; Esperanza B Papadopoulos; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-11       Impact factor: 5.742

Review 7.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

8.  Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.

Authors:  Doris M Ponce; Junting Zheng; Anne Marie Gonzales; Marissa Lubin; Glenn Heller; Hugo Castro-Malaspina; Sergio Giralt; Katharine Hsu; Ann A Jakubowski; Robert R Jenq; Guenther Koehne; Esperanza B Papadopoulos; Miguel A Perales; Marcel R van den Brink; James W Young; Farid Boulad; Nancy A Kernan; Rachel Kobos; Susan Prockop; Andromachi Scaradavou; Trudy Small; Richard J O'Reilly; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

9.  Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation.

Authors:  Andromachi Scaradavou; Katherine M Smith; Rebecca Hawke; Allison Schaible; Michelle Abboud; Nancy A Kernan; James W Young; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-22       Impact factor: 5.742

10.  "No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.

Authors:  Parastoo B Dahi; Doris M Ponce; Sean Devlin; Katherine L Evans; Marissa N Lubin; Anne Marie Gonzales; Joann Tonon; Richard Meagher; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-18       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.